References
- Allen, J.E. and El-Deiry, W.S., 2012. Regulation of the human TRAIL gene. Cancer biology & therapy, 13 (12), 1143–1151.
- Chen, K., et al., 2019. A TRAIL-delvered lipoprotein-bioinspired nanovector engineering stem cell-based platform for inhibition of lung metastasis of melanoma. Theranostics, 9 (10), 2984–2998.
- Hattori, Y., Nakagawa, Y., and Onishi, H., 2019. Gene delivery into hepatic cells with ternary complexes of plasmid DNA, cationic liposomes and apoliprotein E-derived peptide. Experimental and therapeutic medicine, 18 (4), 2628–2638.
- Kearns, M.D., Patel, Y.N., and Savva, M., 2010. Physicochemical characteristics associated with transfection of cationic cholesterol-based gene delivery vectors in the presence of DOPE. Chemistry and physics of lipids, 163 (8), 755–764.
- Kim, B.K., et al., 2015. DOTAP/DOPE ratio and cell type determine transfection efficiency with DOTAP-liposomes. Biochimica et biophysica acta, 1848 (10 Pt A), 1996–2001.
- Martinez-Negro, M., et al., 2018. A Gemini cationic lipid with histidine residues as a novel lipid-based gene nanocarrier: A biophysical and biochemical study. Nanomaterials, 8 (12), 1061.
- Nakamori, M., et al., 2019. Nucleic acid-based therapeutics for Parkinson’s disease. Neurotherapeutics : The journal of the American society for experimental neurotherapeutics, 16 (2), 287–298.
- Nieddu, V., et al., 2019. Engineered human mesenchymal stem cells for neuroblastoma therapeutics. Oncology reports, 42 (1), 35–42.
- Rasoulianboroujeni, M., et al., 2017. Development of a DNA-liposome complex for gene delivery applications. Materials science & engineering. c, materials for biological applications, 75, 191–197.
- Sanitt, P., et al., 2016. Cholesterol-based cationic liposome increases dsRNA protection of yellow head virus infection Penaeus vannamei. Journal of biotechnology, 228, 95–102.
- Sheoran, R., et al., 2019. Recent patents, formulation techniques, classification and characterization of liposomes. Recent patents on nanotechnology, 13 (1), 17–27.
- Weecharangsan, W. and Lee, R.J., 2020. Growth inhibition of combined treatment of cationic liposome/p53 complexes and cisplatin on human carcinoma cells. Journal of applied pharmaceutical science, 10 (4), 34–40.
- Zhang, W.W., et al., 2018. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Human gene therapy, 29 (2), 160–179.
- Zhang, H.H., et al., 2019. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacologica sinica, 40 (11), 1–13.